Investors & Media Home

Mesoblast is a world leader in cell-based medicines.

The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late-stage product candidates.

These allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, orthopedic disorders, oncology and... More

Latest ASX AnnouncementsMore
09 December 2016
New US Accelerated Approval Pathway For Cell Therapies
09 December 2016
S&P DJ Indices Announces December Quarterly Rebalance
06 December 2016
MD Anderson and NIH Fund Trial Using Mesoblast Technologies
22 November 2016
Results of Meeting
Latest Press ReleasesMore
24 February 2016
First Allogeneic Cell Therapy Product Launched in Japan by Mesoblast Licensee
NEW YORK and MELBOURNE, Australia, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MES... 
22 February 2016
Increased Survival Using MSB Cells In Children With aGVHD
17 February 2016
Mesoblast Reports on First Half and Second Quarter Financial Results
MELBOURNE, Australia and NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (... 
16 February 2016
MSB Therapy Shows Benefit In First Cohort Of RA Patients
Upcoming EventsMore
There are currently no events scheduled.
Stock QuoteMore
Exchange :ASX
Price :A$1.31
Change : Stock is Up 0.08 (6.50%)
Volume :1,086,201
Data as of 09 December 2016 4:10 p.m. ET
Data provided by Nasdaq Minimum 15 minutes delay
Download Documentation CEO Presentation to 2016 Annual General Meeting
Download Documentation First Quarter Results Presentation
Download Documentation 2016 Annual Report
Download Documentation 2016 Full Year Results
E-mail Alerts
Sign up to receive e-mail alerts.

Share Price ASX: MSB  AUD 1.31 as of Dec 09, 2016